Lotus Eye Hospital and Institute Limited

NSEI:LOTUSEYE Rapporto sulle azioni

Cap. di mercato: ₹1.6b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Lotus Eye Hospital and Institute Gestione

Gestione criteri di controllo 4/4

Lotus Eye Hospital and Institute's Il CEO è Kuttapalayam Ramalingam, nominato in Aug2020, ha un mandato di 3.5 anni. possiede direttamente 1.43% delle azioni della società, per un valore di ₹ 22.54M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.9 anni e 4.7 anni.

Informazioni chiave

Kuttapalayam Ramalingam

Amministratore delegato

₹1.2m

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEO4.1yrs
Proprietà del CEO1.4%
Durata media del management4yrs
Durata media del Consiglio di amministrazione4.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking

Aug 21
Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking

Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Jan 24
Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 08
Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Jul 15
We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

Apr 07
Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Oct 08
We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 02
Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

Jun 17
If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Mar 11
MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Dec 30
Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

Nov 20
Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

Sep 21
The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

Aug 27
Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Aug 03
Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

Jul 06
Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

AMMINISTRATORE DELEGATO

Kuttapalayam Ramalingam (74 yo)

4.1yrs

Mandato

₹1,200,000

Compensazione

Dr. Kuttapalayam Songappan Ramalingam, M.D., serves as an Executive Director at Lotus Eye Hospital and Institute Limited since February 10, 2021. Dr. Ramalingam serves as Chief Executive Officer at Lotus E...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Kuttapalayam Ramalingam
CEO & Executive Director4.1yrs₹1.20m1.43%
₹ 22.3m
Ramanujam Reghunathan
Chief Financial Officer2.3yrs₹1.70mNessun dato
Mohanmenon Menon
Company Secretary & Compliance Officer2.6yrs₹1.08mNessun dato
Sangeetha Sundaramoorthy
MD & Director4yrs₹3.09m18.84%
₹ 292.4m
Rajkumar Sundaramoorthy
Vice President of Administration6.3yrsNessun dato0.21%
₹ 3.2m

4.0yrs

Durata media

67yo

Età media

Gestione esperta: Il team dirigenziale di LOTUSEYE è considerato esperto (durata media dell'incarico 3.9 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Kuttapalayam Ramalingam
CEO & Executive Director3.6yrs₹1.20m1.43%
₹ 22.3m
Sangeetha Sundaramoorthy
MD & Director4.8yrs₹3.09m18.84%
₹ 292.4m
Rajkumar Sundaramoorthy
Vice President of Administration4.7yrsNessun dato0.21%
₹ 3.2m
Devarayapuram Kaarthikeyan
Non-Executive Independent Director16.9yrs₹200.00kNessun dato
Kavetha Sundaramoorthy
Chairman of the Board8.3yrs₹150.00k18.78%
₹ 291.5m
Yogesh Shah
Non-Executive Independent Director16.9yrs₹200.00kNessun dato
Marappa Alagiriswamy
Non-Executive Independent Director12.3yrs₹200.00kNessun dato
Sengodagounder Natesan
Independent Director3.7yrs₹200.00kNessun dato
Gopalakrishnan Veeramani
Independent Non-Executive Director1.8yrs₹200.00kNessun dato
Perumalsamy Mahendran
Independent Non-Executive Director1.6yrs₹175.00kNessun dato

4.8yrs

Durata media

75yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di LOTUSEYE sono considerati esperti (durata media dell'incarico 4.7 anni).